Skip to Content

Akers Biosciences, Inc. 

Merger

  • Date:
  • 2/11/2021
  • Company Name:
  • Akers Biosciences, Inc.
  • Stock Symbol:
  • AKER
  • Company Name - Buyer:
  • MyMD Pharmaceuticals, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 2/11/2021

Case Finder

Locate any case using the tools below.

NEW YORK, February 11, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Akers Biosciences, Inc. (NASDAQ: AKER) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by MyMD Pharmaceuticals, Inc.  

On November 12, 2020, Akers announced that it had signed an agreement to be acquired by MyMD in an all-stock merger.  Pursuant to the merger agreement, at the close of the merger, Akers stockholders will own approximately 20% of the combined company.  In addition, the merger agreement provides for cash and stock payments to Akers stockholders under certain circumstances.  The deal is scheduled to close in the first half of 2021.

Bragar Eagel & Squire is concerned that Akers’ board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Akers’ stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Akers Biosciences. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: